Pantoprazole

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Pantoprazole

Examples of brand names: Pantozol [DE]

ATC code: A02BC02

Main use (for orientation): Reflux; ulcer

Documented research summary

The associated PPI investigations concern possible interference with cannabinoid urine screening tests. They establish neither a pharmacological interaction nor a safe combination; their results depend on the test method.

Uncertainties and limitations

Oral product information; individual assays, small samples and contradictory methods. The older positive report was inaccessible on repeat retrieval. Do not independently change prescribed medicines on the basis of this research dataset.

Structured assessment

Category: Drug context

Cannabinoid scope: No specifically substantiated pair involving a registered cannabinoid in the material assessed; no claim that all 28 cannabinoids were comprehensively reviewed simultaneously.

Evidence status: Drug properties supported by product information; insufficient evidence for a specific cannabinoid–drug pair effect.

Mechanism / drug context: CYP2C19 demethylation/sulphation and CYP3A4; additional possible assay-dependent diagnostic cross-reactions.

Type of supporting material: Product information and diagnostic investigations; not a cannabinoid pharmacokinetic pair study.

Clinical interpretation: Distinguish test interference from pharmacokinetic or pharmacodynamic cannabinoid interactions.

Context: Two newly read studies found no PPI-related false-positive cannabinoid findings with their respective methods; other reports describe method-dependent reactions.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [VD_LABEL_D0269]: Original product information: drug context, not evidence for a cannabinoid–drug pair

Statement supported: CYP2C19 demethylation/sulphation and CYP3A4; additional possible assay-dependent diagnostic cross-reactions.

Source: PANTOPRAZOLE SODIUM TABLET, DELAYED RELEASE [CARDINAL HEALTH 107, LLC] – DailyMed SPL [VD_LABEL_D0269]

Source role [VD_MED_31566030]: Diagnostics, not a pharmacological interaction

Statement supported: Twelve volunteers taking different PPIs, one test method: no positive tests after administration.

Source: An assessment of urine THC immunoassay in healthy volunteers receiving an oral proton-pump inhibitor. [VD_MED_31566030]

Source role [VD_MED_29126183]: Diagnostics, method-specific

Statement supported: EMIT-II-Plus investigation found no PPI-related false-positive cannabinoid findings.

Source: Up in Smoke: Uncovering a Lack of Evidence for Proton Pump Inhibitors as a Source of Tetrahydrocannabinol Immunoassay False Positives. [VD_MED_29126183]

Source role [VD_MED_28985315]: Diagnostics, historical contrasting finding; full-text access unresolved

Statement supported: Earlier report of pantoprazole cross-reactions with different tests; repeat retrieval was unsuccessful, so no complete new comparison with the original.

Source: Cross-Reactivity of Pantoprazole with Three Commercial Cannabinoids Immunoassays in Urine. [VD_MED_28985315]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: All individual review fields read. Original product information was rechecked only in the relevant pharmacokinetic/interaction excerpts; no complete recertification of all labels or worldwide full-text search. Literature access was based on the previously documented review; only the listed web sources were additionally read in this round. Oral product information; individual assays, small samples and contradictory methods. The older positive report was inaccessible on repeat retrieval.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[VD_LABEL_D0269] PANTOPRAZOLE SODIUM TABLET, DELAYED RELEASE [CARDINAL HEALTH 107, LLC] – DailyMed SPL

Original source / bibliographic reference

Authors: Marketing authorisation holder / label provider according to the linked DailyMed product information

Year: 2026

Source type: Regulatory product information (US SPL)

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VD_MED_31566030] An assessment of urine THC immunoassay in healthy volunteers receiving an oral proton-pump inhibitor.

Original source / bibliographic reference

Authors: Vohra V, Marraffa JM, Wojcik SM, Eggleston W.

Year: 2020

Source type: Journal Article

DOI: 10.1080/15563650.2019.1662917

PMID: 31566030

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

[VD_MED_28985315] Cross-Reactivity of Pantoprazole with Three Commercial Cannabinoids Immunoassays in Urine.

Original source / bibliographic reference

Authors: Gomila I, Barceló B, Rosell A, Avella S, Sahuquillo L, Dastis M.

Year: 2017

Source type: Journal Article

DOI: 10.1093/jat/bkx047

PMID: 28985315

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

[VD_MED_29126183] Up in Smoke: Uncovering a Lack of Evidence for Proton Pump Inhibitors as a Source of Tetrahydrocannabinol Immunoassay False Positives.

Original source / bibliographic reference

Authors: Powers JL, Rasmussen NN, Hurst D, Strathmann FG.

Year: 2018

Source type: Research Support, Non-U.S. Gov't; Journal Article

DOI: 10.1093/pm/pnx266

PMID: 29126183

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

[VD_MED_25733759] 13-year-old girl with recurrent, episodic, persistent vomiting: out of the pot and into the fire.

Original source / bibliographic reference

Authors: Felton D, Zitomersky N, Manzi S, Lightdale JR.

Year: 2015

Source type: Journal Article; Case Reports

DOI: 10.1542/peds.2014-2116

PMID: 25733759

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

[VD_CORR_PPI_29253217] Corrigendum

Original source / bibliographic reference

Authors: Pain Medicine / Oxford University Press; no separate author list

Year: 2019 (online 2017)

Source type: Corrigendum to the article title

DOI: 10.1093/pm/pnx318

PMID: 29253217

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility